Starting a company is a great way to have more freedom in life. Some people want to start a business to earn additional income. Other people do not like working for other people.
Eric Lefkofsky is a successful business owner who enjoys mentoring others. Although he owns a successful company in the health industry, he has experience managing companies in multiple other industries.
Eric Lefkofsky also spends time and money helping people in the local community. He is a firm believer that successful business owners should help those who lack financial resources.
Social media is a powerful tool for marketing to customers. Some business owners do not understand how to utilize social media to increase sales. Eric Lefkofsky is active on social media for several reasons. Not only does he want to expand the brand recognition of his company, but he also wants to help customers as much as possible.
There are numerous social media platforms for business owners to utilize. Social media should be an essential part of marketing for any business owner who wants to increase sales.
Some business ideas require a significant amount of capital. Few people have the cash needed to invest in a new business idea. Eric Lefkofsky is against borrowing too much money in business. With his first company, he borrowed too much money and almost went bankrupt. It took him years to pay down all of his debts.
Venture capital is a proven way to raise money for a business idea. With venture capital, a business owner gives away a portion of their equity in exchange for cash.
In the years ahead, Eric Lefkofsky wants to continue improving sales at Tempus. Although Tempus is a small company, it is making a significant difference in the lives of customers.
Learn More: lefkofskyfoundation.com/about-eric-lefkofsky/
Healthcare charges in the United States have gone too high in the recent years compared to 1990s and before. Records show that $933 billion more was spent on healthcare in 2013 compared to 1996. Part of this figure could be attributed to an increase in population, but the effect of rising medical costs cannot be ignored. Aging is also a factor that contributes to increased doctor visits and a consequent increase in healthcare expenditure.
The JAMA Report
JAMA recently published a report on the analysis of expenditures related to healthcare. One peculiar thing about the report was that Americans were not seen to have changed the frequency in which they sought for medical services over the years. This means that besides the increase in population and the long life expectancy in America, the other prominent healthcare expenditure driver is increased charges. Gerard Anderson of the Bloomberg School of Public Health argued that prices shape the spending curve; the higher the cost, the higher the expenditure will be. Although Gerard took no active role in the 2013 research, he was part of a similar undertaking in 2003. He has been consistent since then that it is the prices that escalate spending, with the recent survey vindicating his claim and more
Joseph Dieleman is of the opinion that different diseases come with various costs. Joseph, one of the senior professionals in the study, gave an example of diabetes whereby about $44 billion out of $64 billion was spent on pharmaceuticals. That said, it is clear that prevalence of diabetes has had a substantial impact on Americans’ expenditure. Another major finding in the research was that even though the duration of patients’ hospital stay has reduced significantly, the cost associated with it has remained stagnant. Joseph Dieleman explained that this was an effect of the increase in daily hospital charges.
The Role of Lefkofsky
Eric Lefkofsky is a co-founder of several firms including Tempus. The 48 years old native of Michigan has been on the front line in trying to find solutions to cancer-related problems. As the CEO of Tempus, Eric has played a key role in ensuring that clinical data on cancer patients is available for physicians’ future use.
Tempus was established only a couple of years back, and to this end, the firm is doing a wonderful job. Eric has led the company in getting partnership deals with institutions like the University of Michigan- his alma mater, Northwestern’s Lurie Cancer Center, and Cleveland Clinic among others. His passion towards helping cancer patients is driven by a personal experience with a cancer patient.
A new Oncotarget article suggests that gut homeostasis plays a crucial role in the bodies of aging individuals. It also suggests that a mTOR specific inhibitor known as rapamycin has enhanced longevity in diverse evolutionary species. The inhibitor reduces the rate at which proliferation takes place in the intestinal cells. Rapamycin also slows down the expansion of microbes in aging guts. It keeps the stem cells active by inhibiting mTOR. These results are used in explaining how lifespan and healthspan can be extended in Drosophila.
IntegraGen’s New EPOC Study
In a move to avail results of a new clinical trial online, IntegraGen released new publication on the Oncotarget online journal. The company’s top scientists got the results after they analyzed miR-31-3p expression in patients’ tumor samples. The publication also explains the relationship between the efficacy of anti-EGFR treatment and miR-31-3p expression. It also explains the findings of the clinical study known as the NEW EPOC Study.Prof. John Bridgewater, a medical oncologist, partnered with other researchers in authoring the report of this innovative study. Prof. Bridgewater, who was also an investigator in the study, said that his team is honored to continue availing clinical research from the New EPOC Study. He mentioned that the data emancipates clinicians on therapies for metastatic colorectal cancer. The data helps in advancing cancer research and enhancing the healthspan and lifespan of patients with metastatic colorectal cancer.IntraGen’s molecular diagnostics director, Yann Gaston-Mathé, pointed out that the study is a manifestation of his company’s commitment to developing precision medicine therapies. Besides posting an article on Oncotarget, IntraGen signed a licensing deal together with CEBRA Laboratories. The deal allows the two companies to collaborate in developing a test that can be used in measuring miR-31-3p expression.
With an impact factor of 5.168, Oncotarget has gained recognition in the field of medicine as an open access and weekly peer-reviewed journal. Its publications cover scientific and clinical research on oncology. Since its release in 2010, Andrei Gudkov and Mikhail Blagosklonny have been serving as the senior editors. Oncotarget’s publications are usually indexed and abstracted in Scopus, Index Medicus/ PubMed, Science Citation Index Expanded and BIOSIS Previews.
Eric Lefkosky is a person with a good heart, a character that is rare to find in many people. Above all, he is an individual richly blessed with the skills to head one of the best corporations in the world today. Presently, Eric Lefkosky is the founding partner and CEO of Tempus. Tempus is a tech hub that tries to explore any available avenue so as to come up with a mechanism better suited to combat cancer.Other companies that Lefkosky has led include Lightbank, Groupon, Uptake Technologies, Mediaocean, Echo Global Logistics, and Inner Workings. Besides, Eric is the brainchild of the Lefkosky Family Foundation, and he also doubles as a trustee of Lurie Children’s Hospital, the Chicago Art Institute, and the science museum based in Chicago. Other dockets that Lefkosky holds today include chairman of Steppenwolf Theater Company, a professor at the University of Chicago, and have also authored a book titled Accelerated Disruption.
Despite his productive work ethics,Eric Lefkosky is an individual with the perfect education background. Presently, he holds a Juris doctorate that was conferred on him in his formative years at the University of Michigan Law School. Thus, he has what it takes to steer systems forward. Of all his ambitions in life, none has been greater than seeing to it that a reliable cure for cancer and breast cancer for that matter has come to fruition.
To attain a universal treatment for breast cancer, Tempus has partnered with other reputable organizations to help speed up the research process. Research is meant to establish trends that characterize many cancer patients, so as to come with a better methodology of combating the deadly ailment.Also, research on breast cancer is meant to provide a database that will help doctors understand what type of cancer they are dealing with so that they can be better placed to treat the disease. Under Eric Lefkosky’s guidance and leadership, Tempus might achieve what it is looking for sooner than we anticipate. With the additional knowledge, fewer people who have cancer will end up dying in future.